KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Notes Payables (2019 - 2025)

Historic Notes Payables for BioNTech SE (BNTX) over the last 7 years, with Q3 2025 value amounting to $45.0 million.

  • BioNTech SE's Notes Payables changed N/A to $45.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year change of. This contributed to the annual value of $2.5 million for FY2023, which is N/A changed from last year.
  • BioNTech SE's Notes Payables amounted to $45.0 million in Q3 2025.
  • BioNTech SE's Notes Payables' 5-year high stood at $309.3 million during Q2 2021, with a 5-year trough of $2.5 million in Q4 2023.
  • In the last 5 years, BioNTech SE's Notes Payables had a median value of $174.4 million in 2022 and averaged $142.6 million.
  • Its Notes Payables has fluctuated over the past 5 years, first plummeted by 3888.79% in 2022, then skyrocketed by 184494.64% in 2025.
  • BioNTech SE's Notes Payables (Quarter) stood at $196.3 million in 2021, then increased by 21.73% to $239.0 million in 2022, then crashed by 98.96% to $2.5 million in 2023, then grew by 0.97% to $2.5 million in 2024, then soared by 1701.33% to $45.0 million in 2025.
  • Its last three reported values are $45.0 million in Q3 2025, $44.7 million for Q2 2025, and $48.6 million during Q1 2025.